ZA200602126B

ZA200602126B - Use of polypeptides of the cupredoxin family in cancer therapy

Use of polypeptides of the cupredoxin family in cancer therapy Download PDF

Info

Publication number: ZA200602126B
Authority: ZA; South Africa
Prior art keywords: azurin; cupredoxin; seq; cells; amino acid
Prior art date: 2003-08-15

Application number

ZA200602126A

Other languages

English (en)

Inventor

Amanda M Chakrabarty

Gupta Tapas K Das

Punj Vasu

Zaborina Olga

Hiraoka Yoshinori

Yamada Tohru

Original Assignee

Univ Illinois

Priority date

2003-08-15

Filing date

2006-03-14

Publication date

2007-09-26

2006-03-14 Application filed by Univ Illinois filed Critical Univ Illinois

2007-09-26 Publication of ZA200602126B publication Critical patent/ZA200602126B/en

Links

108010092351 cupredoxin Proteins 0.000 title claims description 24
108090000765 processed proteins & peptides Proteins 0.000 title description 12
229920001184 polypeptide Polymers 0.000 title description 11
102000004196 processed proteins & peptides Human genes 0.000 title description 11
238000011275 oncology therapy Methods 0.000 title description 2
108010007337 Azurin Proteins 0.000 claims description 136
108090000623 proteins and genes Proteins 0.000 claims description 91
102000004169 proteins and genes Human genes 0.000 claims description 77
206010028980 Neoplasm Diseases 0.000 claims description 66
108010052832 Cytochromes Proteins 0.000 claims description 57
102000018832 Cytochromes Human genes 0.000 claims description 57
230000030833 cell death Effects 0.000 claims description 43
201000011510 cancer Diseases 0.000 claims description 28
108090000051 Plastocyanin Proteins 0.000 claims description 17
108090000035 Pseudoazurin Proteins 0.000 claims description 14
201000001441 melanoma Diseases 0.000 claims description 13
108010086158 rusticyanin Proteins 0.000 claims description 13
108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 11
206010006187 Breast cancer Diseases 0.000 claims description 9
208000026310 Breast neoplasm Diseases 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
206010009944 Colon cancer Diseases 0.000 claims description 5
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
206010033128 Ovarian cancer Diseases 0.000 claims description 5
206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims description 5
208000029742 colonic neoplasm Diseases 0.000 claims description 5
208000032839 leukemia Diseases 0.000 claims description 5
241000605222 Acidithiobacillus ferrooxidans Species 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
241001673062 Achromobacter xylosoxidans Species 0.000 claims description 3
241000588813 Alcaligenes faecalis Species 0.000 claims description 3
241001453201 Phormidium laminosum Species 0.000 claims description 3
241000589516 Pseudomonas Species 0.000 claims description 3
229940005347 alcaligenes faecalis Drugs 0.000 claims description 3
201000005202 lung cancer Diseases 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 10
241000590020 Achromobacter Species 0.000 claims 2
241000588779 Bordetella bronchiseptica Species 0.000 claims 2
201000009906 Meningitis Diseases 0.000 claims 2
241000589342 Methylomonas sp. Species 0.000 claims 2
241000588653 Neisseria Species 0.000 claims 2
241000589540 Pseudomonas fluorescens Species 0.000 claims 2
241000204362 Xylella fastidiosa Species 0.000 claims 2
241000192608 Phormidium Species 0.000 claims 1
230000001737 promoting effect Effects 0.000 claims 1
239000003145 cytotoxic factor Substances 0.000 description 160
210000004027 cell Anatomy 0.000 description 97
210000002540 macrophage Anatomy 0.000 description 80
235000018102 proteins Nutrition 0.000 description 57
241000589513 Burkholderia cepacia Species 0.000 description 50
230000006907 apoptotic process Effects 0.000 description 50
239000000203 mixture Substances 0.000 description 45
238000000034 method Methods 0.000 description 44
150000001413 amino acids Chemical group 0.000 description 37
241000186366 Mycobacterium bovis Species 0.000 description 34
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 31
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 30
229960001456 adenosine triphosphate Drugs 0.000 description 30
239000001963 growth medium Substances 0.000 description 30
230000003013 cytotoxicity Effects 0.000 description 28
231100000135 cytotoxicity Toxicity 0.000 description 28
230000000694 effects Effects 0.000 description 28
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
230000028327 secretion Effects 0.000 description 26
239000006228 supernatant Substances 0.000 description 26
108020004414 DNA Proteins 0.000 description 23
238000011282 treatment Methods 0.000 description 22
230000010261 cell growth Effects 0.000 description 21
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 19
239000003112 inhibitor Substances 0.000 description 19
239000002609 medium Substances 0.000 description 19
244000005700 microbiome Species 0.000 description 19
230000001472 cytotoxic effect Effects 0.000 description 17
230000012010 growth Effects 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
150000001875 compounds Chemical class 0.000 description 15
230000001086 cytosolic effect Effects 0.000 description 15
230000006882 induction of apoptosis Effects 0.000 description 15
238000006467 substitution reaction Methods 0.000 description 15
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 14
102000003855 L-lactate dehydrogenase Human genes 0.000 description 14
108700023483 L-lactate dehydrogenases Proteins 0.000 description 14
241000699660 Mus musculus Species 0.000 description 13
230000035772 mutation Effects 0.000 description 13
238000011580 nude mouse model Methods 0.000 description 13
239000013598 vector Substances 0.000 description 13
235000001014 amino acid Nutrition 0.000 description 12
238000003556 assay Methods 0.000 description 12
239000000284 extract Substances 0.000 description 12
230000002209 hydrophobic effect Effects 0.000 description 12
230000001939 inductive effect Effects 0.000 description 12
230000027756 respiratory electron transport chain Effects 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 11
108090000790 Enzymes Proteins 0.000 description 11
229910052802 copper Inorganic materials 0.000 description 11
239000010949 copper Substances 0.000 description 11
238000002955 isolation Methods 0.000 description 11
210000001539 phagocyte Anatomy 0.000 description 11
125000000539 amino acid group Chemical group 0.000 description 10
239000000872 buffer Substances 0.000 description 10
-1 for example Substances 0.000 description 10
238000005194 fractionation Methods 0.000 description 10
238000013467 fragmentation Methods 0.000 description 10
238000006062 fragmentation reaction Methods 0.000 description 10
210000003630 histaminocyte Anatomy 0.000 description 10
244000000010 microbial pathogen Species 0.000 description 10
244000052769 pathogen Species 0.000 description 10
108090000397 Caspase 3 Proteins 0.000 description 9
102100029855 Caspase-3 Human genes 0.000 description 9
108010059408 apoazurin Proteins 0.000 description 9
238000004624 confocal microscopy Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
230000007613 environmental effect Effects 0.000 description 9
238000011534 incubation Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 8
102000004039 Caspase-9 Human genes 0.000 description 8
108090000566 Caspase-9 Proteins 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
230000001717 pathogenic effect Effects 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
238000002741 site-directed mutagenesis Methods 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
108091093105 Nuclear DNA Proteins 0.000 description 7
230000001640 apoptogenic effect Effects 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
239000000969 carrier Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000000758 substrate Substances 0.000 description 7
102000011727 Caspases Human genes 0.000 description 6
108010076667 Caspases Proteins 0.000 description 6
244000052616 bacterial pathogen Species 0.000 description 6
238000012512 characterization method Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
229910052588 hydroxylapatite Inorganic materials 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
230000003993 interaction Effects 0.000 description 6
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
230000004936 stimulating effect Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000013543 active substance Substances 0.000 description 5
229940098773 bovine serum albumin Drugs 0.000 description 5
238000011161 development Methods 0.000 description 5
239000012634 fragment Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
239000012678 infectious agent Substances 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
230000017074 necrotic cell death Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
102100032534 Adenosine kinase Human genes 0.000 description 4
108020000543 Adenylate kinase Proteins 0.000 description 4
229920000936 Agarose Polymers 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
208000035473 Communicable disease Diseases 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
108010025915 Nitrite Reductases Proteins 0.000 description 4
241000219000 Populus Species 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000007385 chemical modification Methods 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000009918 complex formation Effects 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
230000002950 deficient Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
150000003278 haem Chemical class 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
230000002407 ATP formation Effects 0.000 description 3
241000195585 Chlamydomonas Species 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
239000012614 Q-Sepharose Substances 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
238000012288 TUNEL assay Methods 0.000 description 3
241000607626 Vibrio cholerae Species 0.000 description 3
239000003708 ampul Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000003127 anti-melanomic effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
229910002091 carbon monoxide Inorganic materials 0.000 description 3
230000006369 cell cycle progression Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
239000002254 cytotoxic agent Substances 0.000 description 3
231100000599 cytotoxic agent Toxicity 0.000 description 3
230000007123 defense Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000009509 drug development Methods 0.000 description 3
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
238000001476 gene delivery Methods 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
210000003470 mitochondria Anatomy 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000006384 oligomerization reaction Methods 0.000 description 3
239000003642 reactive oxygen metabolite Substances 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
201000008827 tuberculosis Diseases 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
ZMZRKOASUWINDA-VEABSNGSSA-N (4s)-4-[[(2s)-2-amino-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O ZMZRKOASUWINDA-VEABSNGSSA-N 0.000 description 2
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
108010035679 Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Leu-Glu-His-Asp-Cho Proteins 0.000 description 2
241000590022 Achromobacter cycloclastes Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010008631 Cholera Diseases 0.000 description 2
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
108010075021 Cytochromes f Proteins 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000005720 Glutathione transferase Human genes 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000530268 Lycaena heteronea Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000012979 RPMI medium Substances 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
239000012505 Superdex™ Substances 0.000 description 2
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
229910052770 Uranium Inorganic materials 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
229950006790 adenosine phosphate Drugs 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
108010051758 aspartyl-glutamyl-valyl-aspartal Proteins 0.000 description 2
108010078837 aspartyl-glutamyl-valyl-aspartyl-p-nitroanilide Proteins 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
229910001431 copper ion Inorganic materials 0.000 description 2
108010018850 cytochrome C(551) Proteins 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
239000008298 dragée Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000037041 intracellular level Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
201000005296 lung carcinoma Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
210000001700 mitochondrial membrane Anatomy 0.000 description 2
231100000219 mutagenic Toxicity 0.000 description 2
230000003505 mutagenic effect Effects 0.000 description 2
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000004987 nonapoptotic effect Effects 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000013049 sediment Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
241001453369 Achromobacter denitrificans Species 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000959322 Aporus Species 0.000 description 1
241000244038 Brugia malayi Species 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
102000011632 Caseins Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
241000192700 Cyanobacteria Species 0.000 description 1
102000005927 Cysteine Proteases Human genes 0.000 description 1
108010005843 Cysteine Proteases Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
102100030497 Cytochrome c Human genes 0.000 description 1
108010075031 Cytochromes c Proteins 0.000 description 1
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108091006149 Electron carriers Proteins 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
AYIZHKDZYOSOGY-IUCAKERBSA-N His-Met Chemical compound CSCC[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CN=CN1 AYIZHKDZYOSOGY-IUCAKERBSA-N 0.000 description 1
238000012313 Kruskal-Wallis test Methods 0.000 description 1
241000222724 Leishmania amazonensis Species 0.000 description 1
239000007987 MES buffer Substances 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102220538475 Methionine-tRNA ligase, cytoplasmic_K85P_mutation Human genes 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
241001467552 Mycobacterium bovis BCG Species 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102000000033 Purinergic Receptors Human genes 0.000 description 1
108010080192 Purinergic Receptors Proteins 0.000 description 1
239000012564 Q sepharose fast flow resin Substances 0.000 description 1
102220490404 S-adenosylhomocysteine hydrolase-like protein 1_S66A_mutation Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000195663 Scenedesmus Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
241000605118 Thiobacillus Species 0.000 description 1
241000592342 Tracheophyta Species 0.000 description 1
102220495868 Translocation protein SEC62_H83F_mutation Human genes 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
102100033254 Tumor suppressor ARF Human genes 0.000 description 1
241000196252 Ulva Species 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
239000000370 acceptor Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
102220360648 c.155C>A Human genes 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
239000002820 chemotaxin Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000003763 chloroplast Anatomy 0.000 description 1
208000016532 chronic granulomatous disease Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-L cysteinate(2-) Chemical compound [S-]CC(N)C([O-])=O XUJNEKJLAYXESH-UHFFFAOYSA-L 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000003473 flash photolysis reaction Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000005661 hydrophobic surface Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000010820 immunofluorescence microscopy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
231100000405 induce cancer Toxicity 0.000 description 1
239000000411 inducer Substances 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
244000000074 intestinal pathogen Species 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
208000020442 loss of weight Diseases 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
150000002669 lysines Chemical class 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000036457 multidrug resistance Effects 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
244000039328 opportunistic pathogen Species 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
108700025694 p53 Genes Proteins 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000029553 photosynthesis Effects 0.000 description 1
238000010672 photosynthesis Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
102220235007 rs1131691186 Human genes 0.000 description 1
102220094059 rs755931648 Human genes 0.000 description 1
102220118331 rs886041280 Human genes 0.000 description 1
102220279444 rs988441570 Human genes 0.000 description 1
239000005060 rubber Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000001974 tryptic soy broth Substances 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
239000000225 tumor suppressor protein Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000007473 univariate analysis Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000001018 virulence Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000012982 x-ray structure analysis Methods 0.000 description 1
235000021246 κ-casein Nutrition 0.000 description 1